Equities analysts expect Tandem Diabetes Care Inc (NASDAQ:TNDM) to announce ($1.28) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Tandem Diabetes Care’s earnings, with the highest EPS estimate coming in at ($1.19) and the lowest estimate coming in at ($1.37). Tandem Diabetes Care posted earnings of ($4.80) per share during the same quarter last year, which indicates a positive year over year growth rate of 73.3%. The business is expected to announce its next earnings report after the market closes on Thursday, March 1st.
According to Zacks, analysts expect that Tandem Diabetes Care will report full-year earnings of ($15.15) per share for the current year, with EPS estimates ranging from ($16.99) to ($13.31). For the next year, analysts anticipate that the business will report earnings of ($4.97) per share, with EPS estimates ranging from ($6.15) to ($2.87). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Tandem Diabetes Care.
TNDM has been the topic of several research analyst reports. Zacks Investment Research raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a report on Wednesday, December 6th. Robert W. Baird reaffirmed a “hold” rating and issued a $3.00 price target on shares of Tandem Diabetes Care in a research note on Sunday, November 19th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $11.29.
Shares of Tandem Diabetes Care (NASDAQ:TNDM) traded up $0.02 on Wednesday, reaching $2.43. The company’s stock had a trading volume of 739,400 shares, compared to its average volume of 951,415. The company has a debt-to-equity ratio of -2.70, a quick ratio of 0.88 and a current ratio of 1.90. Tandem Diabetes Care has a one year low of $2.14 and a one year high of $26.00. The firm has a market capitalization of $24.59, a price-to-earnings ratio of -0.12 and a beta of 0.44.
In related news, CEO Kim D. Blickenstaff acquired 750,000 shares of the stock in a transaction on Friday, February 9th. The shares were bought at an average price of $2.00 per share, with a total value of $1,500,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher J. Twomey acquired 75,000 shares of the stock in a transaction on Friday, February 9th. The shares were bought at an average cost of $2.00 per share, for a total transaction of $150,000.00. The disclosure for this purchase can be found here. Insiders own 20.90% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wedbush Securities Inc. boosted its stake in Tandem Diabetes Care by 88.6% during the third quarter. Wedbush Securities Inc. now owns 188,877 shares of the medical device company’s stock worth $138,000 after buying an additional 88,709 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Tandem Diabetes Care by 13.5% during the third quarter. Russell Investments Group Ltd. now owns 659,993 shares of the medical device company’s stock worth $482,000 after buying an additional 78,748 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Tandem Diabetes Care by 2.7% during the second quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock worth $987,000 after buying an additional 32,991 shares during the last quarter.
TRADEMARK VIOLATION WARNING: This piece was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://ledgergazette.com/2018/02/19/1-28-earnings-per-share-expected-for-tandem-diabetes-care-inc-tndm-this-quarter.html.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.